Floatz logo

Pregabalin

Chronic Low Back Pain With a Neuropathic Component

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Small moleculePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Chronic Low Back Pain With a Neuropathic Component cohort.

Asset / SponsorPhaseRating
Dfn-15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB

Same molecule, other indications

Pregabalin is also rated in:

neuralgiaDormant
A
Indicative ·
82 / 100
View asset →
peripheral neuropathyDormant
A
Indicative ·
82 / 100
View asset →
focal epilepsyDormant
A
Indicative ·
82 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →